Ligand Pharmaceuticals Inc. (LGND) Stake Boosted by Janus Henderson Group PLC

Janus Henderson Group PLC increased its holdings in shares of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) by 26.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 754,692 shares of the biotechnology company’s stock after purchasing an additional 159,201 shares during the period. Janus Henderson Group PLC owned approximately 3.58% of Ligand Pharmaceuticals worth $102,751,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Strs Ohio lifted its stake in Ligand Pharmaceuticals by 225.0% in the 2nd quarter. Strs Ohio now owns 1,300 shares of the biotechnology company’s stock valued at $157,000 after acquiring an additional 900 shares in the last quarter. First Mercantile Trust Co. lifted its stake in Ligand Pharmaceuticals by 1.6% in the 2nd quarter. First Mercantile Trust Co. now owns 1,310 shares of the biotechnology company’s stock valued at $159,000 after acquiring an additional 20 shares in the last quarter. Teacher Retirement System of Texas bought a new stake in Ligand Pharmaceuticals in the 2nd quarter valued at approximately $203,000. Harbor Advisors LLC bought a new stake in Ligand Pharmaceuticals in the 3rd quarter valued at approximately $204,000. Finally, Round Table Services LLC bought a new stake in Ligand Pharmaceuticals in the 3rd quarter valued at approximately $205,000.

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) opened at $136.04 on Friday. The firm has a market capitalization of $2,899.47, a P/E ratio of 103.29, a price-to-earnings-growth ratio of 2.11 and a beta of 0.91. Ligand Pharmaceuticals Inc. has a 1 year low of $95.08 and a 1 year high of $149.31. The company has a debt-to-equity ratio of 0.05, a quick ratio of 0.95 and a current ratio of 0.97.

Ligand Pharmaceuticals (NASDAQ:LGND) last posted its quarterly earnings results on Thursday, November 9th. The biotechnology company reported $0.69 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.37 by $0.32. The firm had revenue of $33.38 million for the quarter, compared to analyst estimates of $31.04 million. Ligand Pharmaceuticals had a return on equity of 7.83% and a net margin of 12.76%. The business’s quarterly revenue was up 54.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.62 EPS. sell-side analysts forecast that Ligand Pharmaceuticals Inc. will post 2.37 earnings per share for the current fiscal year.

Several equities research analysts have commented on the company. Zacks Investment Research cut Ligand Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, November 30th. Roth Capital set a $158.00 price target on Ligand Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, November 13th. Craig Hallum reaffirmed a “buy” rating and set a $170.00 price target (up previously from $160.00) on shares of Ligand Pharmaceuticals in a research report on Wednesday, November 15th. Finally, HC Wainwright set a $159.00 price target on Ligand Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, November 15th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $149.67.

In related news, VP Matthew E. Korenberg sold 6,559 shares of the business’s stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $142.63, for a total transaction of $935,510.17. Following the transaction, the vice president now directly owns 8,147 shares of the company’s stock, valued at approximately $1,162,006.61. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director John W. Kozarich sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, November 16th. The stock was sold at an average price of $141.71, for a total value of $708,550.00. Following the transaction, the director now directly owns 35,649 shares in the company, valued at $5,051,819.79. The disclosure for this sale can be found here. Insiders have sold a total of 16,828 shares of company stock worth $2,395,051 in the last ninety days. Insiders own 8.30% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Ligand Pharmaceuticals Inc. (LGND) Stake Boosted by Janus Henderson Group PLC” was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://stocknewstimes.com/2017/12/15/ligand-pharmaceuticals-inc-lgnd-stake-boosted-by-janus-henderson-group-plc.html.

Ligand Pharmaceuticals Company Profile

Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals.

Want to see what other hedge funds are holding LGND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ligand Pharmaceuticals Inc. (NASDAQ:LGND).

Institutional Ownership by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)

Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply